Omeros Corporation Overview
Industry: Biotechnology
Sector: Healthcare
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical progra Read MoreReported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $32.2M (reported). Operating income was $0.1M. Net loss was -$17.1M.
Revenue
$32.2M
reported
Operating income
$0.1M
reported
Net loss
-$17.1M
reported
Net income
$13.2M
-152% YoY
What changed
- Revenue reported to $32.2M.
- Net income -152% YoY to $13.2M.
Guidance / outlook
we expect enrollment to begin in two investigator-sponsored and Omeros-supported studies, one evaluating YARTEMLEA in hyperinflammatory ARDS, and the other assessing prophylactic YARTEMLEA in pediatric patients with predictably severe TA-TMA.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
FORM 8-K
Aug 12, 2026
SEC filing
FORM 10-Q
Aug 12, 2026
SEC filing
FORM 10-Q
May 13, 2026
Earnings release
EXHIBIT 99.1
May 13, 2026
SEC filing
FORM 8-K
May 13, 2026
Earnings release
EXHIBIT 99.1
Mar 31, 2026
SEC filing
FORM 10-K
Mar 31, 2026
SEC filing
FORM 8-K
Mar 31, 2026
SEC filing
FORM 8-K
Jan 07, 2026
SEC filing
FORM 10-Q
Nov 13, 2025
SEC filing
FORM 8-K
Nov 13, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Omeros (OMER) Q2 Earnings and Revenues Beat Estimates
Headline from Yahoo Finance: Omeros (OMER) Q2 Earnings and Revenues Beat Estimates.
Earnings call transcript: Omeros Q2 2026 beats estimates, shares jump 20%
Headline from Investing.com Nigeria: Earnings call transcript: Omeros Q2 2026 beats estimates, shares jump 20%.
Earnings call transcript: Omeros Q2 2026 beats estimates, shares jump 20%
Headline from Investing.com: Earnings call transcript: Omeros Q2 2026 beats estimates, shares jump 20%.
Omeros Corporation Q2 2026 Earnings Call Summary
Headline from Yahoo Finance: Omeros Corporation Q2 2026 Earnings Call Summary.
Omeros Q2 Earnings Call Highlights
Headline from Yahoo Finance: Omeros Q2 Earnings Call Highlights.
Omeros earnings beat by $0.27, revenue topped estimates
Headline from Investing.com: Omeros earnings beat by $0.27, revenue topped estimates.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.